Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

Abdullah A. Osman; David M. Neskey; Panagiotis Katsonis; Ameeta A. Patel; Alexandra M. Ward; Teng Kuei Hsu; Stephanie C. Hicks; Thomas O. McDonald; Thomas J. Ow; Marcus Ortega Alves; Curtis R. Pickering; Heath D. Skinner; Mei Zhao; Eric M. Sturgis; Merrill S. Kies; Adel El-Naggar; Federica Perrone; Lisa Licitra; Paolo Bossi; Marek Kimme; Mitchell J. Frederick; Olivier Lichtarge; Jeffrey N. Myers

doi:10.1158/0008-5472.CAN-14-2729

Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

Abdullah A. Osman, David M. Neskey, Panagiotis Katsonis, Ameeta A. Patel, Alexandra M. Ward, Teng Kuei Hsu, Stephanie C. Hicks, Thomas O. McDonald, Thomas J. Ow, Marcus Ortega Alves, Curtis R. Pickering, Heath D. Skinner, Mei Zhao, Eric M. Sturgis, Merrill S. Kies, Adel El-Naggar, Federica Perrone, Lisa Licitra, Paolo Bossi, Marek KimmeMitchell J. Frederick, Olivier Lichtarge, Jeffrey N. Myers

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.

Original language	English (US)
Pages (from-to)	1205-1215
Number of pages	11
Journal	Cancer Research
Volume	75
Issue number	7
DOIs	https://doi.org/10.1158/0008-5472.CAN-14-2729
State	Published - Apr 1 2015
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/0008-5472.CAN-14-2729

Cite this

Osman, A. A., Neskey, D. M., Katsonis, P., Patel, A. A., Ward, A. M., Hsu, T. K., Hicks, S. C., McDonald, T. O., Ow, T. J., Alves, M. O., Pickering, C. R., Skinner, H. D., Zhao, M., Sturgis, E. M., Kies, M. S., El-Naggar, A., Perrone, F., Licitra, L., Bossi, P., ... Myers, J. N. (2015). Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Research, 75(7), 1205-1215. https://doi.org/10.1158/0008-5472.CAN-14-2729

Osman, AA, Neskey, DM, Katsonis, P, Patel, AA, Ward, AM, Hsu, TK, Hicks, SC, McDonald, TO, Ow, TJ, Alves, MO, Pickering, CR, Skinner, HD, Zhao, M, Sturgis, EM, Kies, MS, El-Naggar, A, Perrone, F, Licitra, L, Bossi, P, Kimme, M, Frederick, MJ, Lichtarge, O & Myers, JN 2015, 'Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients', Cancer Research, vol. 75, no. 7, pp. 1205-1215. https://doi.org/10.1158/0008-5472.CAN-14-2729

@article{62b90ab1488847cca4e360ef8b828958,

title = "Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients",

abstract = "TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.",

author = "Osman, {Abdullah A.} and Neskey, {David M.} and Panagiotis Katsonis and Patel, {Ameeta A.} and Ward, {Alexandra M.} and Hsu, {Teng Kuei} and Hicks, {Stephanie C.} and McDonald, {Thomas O.} and Ow, {Thomas J.} and Alves, {Marcus Ortega} and Pickering, {Curtis R.} and Skinner, {Heath D.} and Mei Zhao and Sturgis, {Eric M.} and Kies, {Merrill S.} and Adel El-Naggar and Federica Perrone and Lisa Licitra and Paolo Bossi and Marek Kimme and Frederick, {Mitchell J.} and Olivier Lichtarge and Myers, {Jeffrey N.}",

note = "Publisher Copyright: {\textcopyright}2015 AACR.",

year = "2015",

month = apr,

day = "1",

doi = "10.1158/0008-5472.CAN-14-2729",

language = "English (US)",

volume = "75",

pages = "1205--1215",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

TY - JOUR

T1 - Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

AU - Osman, Abdullah A.

AU - Neskey, David M.

AU - Katsonis, Panagiotis

AU - Patel, Ameeta A.

AU - Ward, Alexandra M.

AU - Hsu, Teng Kuei

AU - Hicks, Stephanie C.

AU - McDonald, Thomas O.

AU - Ow, Thomas J.

AU - Alves, Marcus Ortega

AU - Pickering, Curtis R.

AU - Skinner, Heath D.

AU - Zhao, Mei

AU - Sturgis, Eric M.

AU - Kies, Merrill S.

AU - El-Naggar, Adel

AU - Perrone, Federica

AU - Licitra, Lisa

AU - Bossi, Paolo

AU - Kimme, Marek

AU - Frederick, Mitchell J.

AU - Lichtarge, Olivier

AU - Myers, Jeffrey N.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.

AB - TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=84930967437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930967437&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2729

DO - 10.1158/0008-5472.CAN-14-2729

M3 - Article

C2 - 25691460

AN - SCOPUS:84930967437

SN - 0008-5472

VL - 75

SP - 1205

EP - 1215

JO - Cancer Research

JF - Cancer Research

IS - 7

ER -

Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this